Review
Urology & Nephrology
Donald E. Kohan, Jonathan Barratt, Hiddo J. Heerspink, Kirk N. Campbell, Mariannne Camargo, Ike Ogbaa, Ruth Haile-Meskale, Dana V. Rizk, Andrew King
Summary: Immunoglobulin A nephropathy (IgAN) is a common primary glomerulonephritis worldwide. New therapies, including endothelin-A receptor (ETAR) blockade, show promise for mitigating renal deterioration and reducing proteinuria in patients with IgAN.
KIDNEY INTERNATIONAL REPORTS
(2023)
Article
Endocrinology & Metabolism
Dong-Yuan Chang, Meng-Rui Li, Xiao-Juan Yu, Su-Xia Wang, Min Chen, Ming-Hui Zhao
Summary: In this study, it was found that compared to proteinuric DN patients, nonproteinuric DN patients had lower frequency of diabetic retinopathy (DR) and better renal outcomes.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Medicine, Research & Experimental
Xiandeng Li, Ying Zhang, Xiaodong Xing, Mi Li, Yan Liu, Ajing Xu, Jian Zhang
Summary: Diabetic nephropathy is a severe complication of diabetes mellitus, and understanding the underlying mechanisms of podocyte injury is key to developing effective therapeutic interventions. This review summarizes the factors contributing to podocyte injury in DN, including lipotoxicity, hemodynamic abnormalities, oxidative stress, mitochondrial dysfunction, and impaired autophagy. The findings presented in this review provide potential therapeutic targets and strategies for the management of DN associated with podocyte injury.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Urology & Nephrology
J. David Smeijer, Donald E. Kohan, David J. Webb, Neeraj Dhaun, Hiddo J. L. Heerspink
Summary: Endothelin receptor antagonists show significant kidney protection in patients with diabetic kidney disease, with potential therapeutic effects in non-diabetic kidney diseases such as IgA nephropathy and FSGS.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
(2021)
Article
Pharmacology & Pharmacy
Mahyar Khazaeli, Ane C. F. Nunes, Yitong Zhao, Mahziar Khazaeli, John Prudente, Nosratola D. Vaziri, Bhupinder Singh, Wei Ling Lau
Summary: In a rat model of type 2 diabetes mellitus, the effects of tetrahydrocurcumin (THC) were examined on kidney oxidative stress and fibrosis as add-on therapy to losartan. The combination treatment of THC, PPC, and losartan significantly improved antioxidant levels, decreased fibrosis, and lowered blood pressure in diabetic CKD rats.
PHARMACOLOGY RESEARCH & PERSPECTIVES
(2023)
Article
Cell Biology
Lingfei Li, Yanhai Feng, Junhui Zhang, Qiong Zhang, Jun Ren, Cheng Sun, Shujing Li, Xia Lei, Gaoxing Luo, Jiongyu Hu, Yuesheng Huang
Summary: In this study, the researchers investigated the role of MAP4 phosphorylation in causing proteinuria in diabetic nephropathy (DN). They found that the content of p-MAP4 was increased in the urine samples of diabetic patients and in the kidney tissues of diabetic mice. p-MAP4 triggered proteinuria by inducing epithelial-to-mesenchymal transition and apoptosis in podocytes. The study also showed that mice with MAP4 hyperphosphorylation were more susceptible to a certain diabetes treatment and exhibited more severe DN pathology compared to wild-type mice. In vitro experiments further revealed that high glucose triggered the elevation of p-MAP4 and various pathological changes in podocytes, which were rectified by MAP4 dephosphorylation. The findings suggest that p-MAP4 plays a novel role in causing proteinuria in DN and indicate the therapeutic potential of MAP4 in protecting against proteinuria and related diseases.
CELL COMMUNICATION AND SIGNALING
(2022)
Article
Law
Lindsay Wilson
Summary: Following the Supreme Court decision on AMG Capital Management, LLC v. FTC, there are concerns about the FTC's ability to police the marketplace effectively. Dark patterns, deceptive online practices designed to trick users, continue to proliferate. This article argues that an FTC-promulgated rule prohibiting the use of dark patterns would benefit consumers, regulators, and businesses, providing clarity, efficient litigation, and protection from deceptive practices.
GEORGE WASHINGTON LAW REVIEW
(2023)
Article
Pharmacology & Pharmacy
Baranca Buijsers, Marjolein Garsen, Mark de Graaf, Marinka Bakker-van Bebber, Chunming Guo, Xue Li, Johan van der Vlag
Summary: The study explores the therapeutic potential of inhibiting the endothelial glycocalyx degrading enzyme HPSE1 in kidney diseases. It suggests that HPSE2, a structural homolog of HPSE1 without enzymatic activity, could be a promising HPSE1 inhibitor. The downregulation of HPSE2 under inflammatory and diabetic conditions, and the protective effect of HPSE2 in experimental glomerular diseases support the notion that HPSE2 could be used as a therapeutic strategy for glomerular diseases.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Medicine, General & Internal
Noorain Ahmad, Harish Veerapalli, Chetan Reddy Lankala, Everardo E. Castaneda, Afia Aziz, Amy G. Rockferry, Pousette Hamid
Summary: This systematic review found that endothelin receptor antagonists in combination with renin-angiotensin-aldosterone system inhibitors effectively reduce albuminuria and prevent the progression of diabetic kidney disease. However, more extensive clinical trials are still needed to confirm these relationships.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Review
Pharmacology & Pharmacy
Daiji Kawanami, Yuichi Takashi, Yoshimi Muta, Naoki Oda, Dai Nagata, Hiroyuki Takahashi, Makito Tanabe
Summary: Diabetic kidney disease is a major cause of end-stage kidney disease worldwide, with the mineralocorticoid receptor playing an important role in its development. Clinical studies have shown the benefits of MR antagonists for DKD, but concerns remain about their selectivity and hyperkalemia risks. New nonsteroidal MRAs, such as finerenone, have been developed with high selectivity and potent anti-inflammatory and anti-fibrotic properties, and a lower risk of hyperkalemia.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Plant Sciences
Ting-Ting Chang, Yi-An Chen, Szu-Yuan Li, Jaw-Wen Chen
Summary: The study showed that Ginkgo biloba extract (GbE) prevented diabetic nephropathy (DN) by activating heme oxygenase (HO)-1, improving renal function, decreasing glomerular hypertrophy, proteinuria, and kidney/body weight ratio, reducing inflammatory factors in the glomeruli, and protecting podocytes against the effects of high glucose.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)
Article
Peripheral Vascular Disease
Tae-Hyun Yoo, Soon Jun Hong, Sunggyun Kim, Seokjoon Shin, Dong Ki Kim, Jung Pyo Lee, Sang Youb Han, Sangho Lee, Jong Chul Won, Young Sun Kang, Jongha Park, Byoung-Geun Han, Ki-Ryang Na, Kyu Yeon Hur, Yong-Jin Kim, Sungha Park
Summary: This study compares the antiproteinuric effects of fimasartan and losartan in patients with diabetic kidney disease. The results show that fimasartan significantly reduces albuminuria compared to losartan, even after adjusting for systolic blood pressure levels. There were no significant differences in adverse events between the two drugs.
HYPERTENSION RESEARCH
(2022)
Review
Urology & Nephrology
Edmund Y. M. Chung, Sunil Badve, Hiddo J. L. Heerspink, Muh Geot Wong
Summary: The burden of chronic kidney disease is increasing globally due to the rise in diabetes and hypertension. Current treatments, such as renin angiotensin system inhibitors, are only partially effective, highlighting the need for additional therapies to prevent kidney failure. Endothelin receptor antagonism shows promise in protecting the kidneys from further damage and may be used in both diabetic and non-diabetic kidney disease.
Review
Infectious Diseases
Leon G. Leanse, Sanjay Marasini, Carolina dos Anjos, Tianhong Dai
Summary: In recent years, the global population has faced a serious threat of antimicrobial resistance (AMR) due to the increase in microorganisms with multiple AMR mechanisms. The COVID-19 pandemic has further worsened the situation by causing an influx of infections caused by multidrug-resistant organisms (MDROs), putting enormous pressure on healthcare systems. Light-based approaches have been proposed as a potential solution to combat both cancer and infectious diseases for over a century. These approaches are effective in killing microbial pathogens regardless of their AMR status and are less likely to result in the development of resistance. This review aims to describe the different mechanisms driving AMR and discuss light-based approaches such as antimicrobial photodynamic therapy (aPDT), antimicrobial blue light (aBL), and ultraviolet (UV) light as potential alternatives or adjunct therapies to conventional antimicrobials. The feasibility and requirements of integrating light-based approaches into clinical practice will also be evaluated.
Article
Endocrinology & Metabolism
Tatsuhiko Azegami, Takashin Nakayama, Kaori Hayashi, Akihito Hishikawa, Norifumi Yoshimoto, Ran Nakamichi, Hiroshi Itoh
Summary: The development of the RAGE vaccine successfully attenuated the progression of diabetic kidney disease in mice and offers a promising therapeutic strategy for patients with DKD.
